Analysis of the Molecular Networks in Androgen Dependent and Independent Prostate Cancer Revealed Fragile and Robust Subsystems

Androgen ablation therapy is currently the primary treatment for metastatic prostate cancer. Unfortunately, in nearly all cases, androgen ablation fails to permanently arrest cancer progression. As androgens like testosterone are withdrawn, prostate cancer cells lose their androgen sensitivity and begin to proliferate without hormone growth factors. In this study, we constructed and analyzed a mathematical model of the integration between hormone growth factor signaling, androgen receptor activation, and the expression of cyclin D and Prostate-Specific Antigen in human LNCaP prostate adenocarcinoma cells. The objective of the study was to investigate which signaling systems were important in the loss of androgen dependence. The model was formulated as a set of ordinary differential equations which described 212 species and 384 interactions, including both the mRNA and protein levels for key species. An ensemble approach was chosen to constrain model parameters and to estimate the impact of parametric uncertainty on model predictions. Model parameters were identified using 14 steady-state and dynamic LNCaP data sets taken from literature sources. Alterations in the rate of Prostatic Acid Phosphatase expression was sufficient to capture varying levels of androgen dependence. Analysis of the model provided insight into the importance of network components as a function of androgen dependence. The importance of androgen receptor availability and the MAPK/Akt signaling axes was independent of androgen status. Interestingly, androgen receptor availability was important even in androgen-independent LNCaP cells. Translation became progressively more important in androgen-independent LNCaP cells. Further analysis suggested a positive synergy between the MAPK and Akt signaling axes and the translation of key proliferative markers like cyclin D in androgen-independent cells. Taken together, the results support the targeting of both the Akt and MAPK pathways. Moreover, the analysis suggested that direct targeting of the translational machinery, specifically eIF4E, could be efficacious in androgen-independent prostate cancers.

[1]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[2]  Robert J. Gelinas,et al.  Sensitivity analysis of ordinary differential equation systems—A direct method , 1976 .

[3]  P. Vihko.  Human prostatic acid phosphatases: purification of a minor enzyme and comparisons of the enzymes. , 1979, Investigative urology.

[4]  G. Murphy,et al.  A prostate antigen in sera of prostatic cancer patients. , 1980, Cancer research.

[5]  G. Murphy,et al.  Prostate antigen: A new potential marker for prostatic cancer , 1981, The Prostate.

[6]  G. Murphy,et al.  Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. , 1982, Journal of the National Cancer Institute.

[7]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[8]  G. Clinton,et al.  The epidermal growth factor receptor from prostate cells is dephosphorylated by a prostate-specific phosphotyrosyl phosphatase. , 1988, Molecular and cellular biology.

[9]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[10]  Michael J. Wilson,et al.  Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the gleason grading system , 1988, The Prostate.

[11]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[12]  B. O’Malley,et al.  Steroid receptor family: structure and functions. , 1990, Endocrine reviews.

[13]  P. Riegman,et al.  The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. , 1991, Molecular endocrinology.

[14]  H. Kanetake,et al.  Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma , 1991, The Prostate.

[15]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[16]  P. Wilkie.  Ethical issues in urology: the patient's perspective. , 1995, British journal of urology.

[17]  J. Mcconnell.  Prostatic growth: new insights into hormonal regulation. , 1995, British journal of urology.

[18]  J. Bartek,et al.  Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint , 1996, Molecular and cellular biology.

[19]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[20]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[21]  Chi-Ying F. Huang,et al.  Ultrasensitivity in the mitogen-activated protein kinase cascade. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[23]  T. Meng,et al.  Tyrosine Phosphorylation of c-ErbB-2 Is Regulated by the Cellular Form of Prostatic Acid Phosphatase in Human Prostate Cancer Cells* , 1998, The Journal of Biological Chemistry.

[24]  N. Bruchovsky,et al.  Prostate cancer: molecular biology of early progression to androgen independence. , 1999, Endocrine-related cancer.

[25]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[26]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Kholodenko,et al.  Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor* , 1999, The Journal of Biological Chemistry.

[28]  M. Fussenegger,et al.  A mathematical model of caspase function in apoptosis , 2000, Nature Biotechnology.

[29]  Ming-Shyue Lee,et al.  Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells , 2000, Oncogene.

[30]  M. Wilkinson,et al.  Control of the eukaryotic cell cycle by MAP kinase signaling pathways , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  Ming-Shyue Lee,et al.  DIFFERENTIAL RESPONSIVENESS OF PROSTATIC ACID PHOSPHATASE AND PROSTATE‐SPECIFIC ANTIGEN mRNA TO ANDROGEN IN PROSTATE CANCER CELLS , 2000, Cell biology international.

[32]  H. Klocker,et al.  Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides , 2000, Cancer Gene Therapy.

[33]  D. Lauffenburger,et al.  A Computational Study of Feedback Effects on Signal Dynamics in a Mitogen‐Activated Protein Kinase (MAPK) Pathway Model , 2001, Biotechnology progress.

[34]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[35]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[36]  S. Yeh,et al.  Identification and characterization of androgen receptor associated coregulators in prostate cancer cells. , 2001, Journal of biological regulators and homeostatic agents.

[37]  J. Arnold,et al.  An ensemble method for identifying regulatory circuits with special reference to the qa gene cluster of Neurospora crassa , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Gelmann,et al.  Molecular biology of the androgen receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[40]  E. Gilles,et al.  Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors , 2002, Nature Biotechnology.

[41]  S. Batra,et al.  Establishment and characterization of androgen‐independent human prostate cancer LNCaP cell model , 2002, The Prostate.

[42]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[43]  Ming-Shyue Lee,et al.  ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells , 2003, Oncogene.

[44]  S. Monti,et al.  Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. , 2003, Anticancer research.

[45]  Ming-Fong Lin,et al.  Suppression of LNCaP prostate cancer xenograft tumors by a prostate‐specific protein tyrosine phosphatase, prostatic acid phosphatase , 2003, The Prostate.

[46]  G. Mills,et al.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.

[47]  K. S. Brown,et al.  Statistical mechanical approaches to models with many poorly known parameters. , 2003, Physical review. E, Statistical, nonlinear, and soft matter physics.

[48]  E. Crawford,et al.  The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial , 2004, The Prostate.

[49]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[50]  Jeremy S Edwards,et al.  MAPK cascade possesses decoupled controllability of signal amplification and duration. , 2004, Biophysical journal.

[51]  K. H. Lee,et al.  The statistical mechanics of complex signaling networks: nerve growth factor signaling , 2004, Physical biology.

[52]  G. Coetzee,et al.  Prostate specific antigen gene regulation by androgen receptor , 2004, Journal of cellular biochemistry.

[53]  J. Stelling,et al.  Robustness properties of circadian clock architectures. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[54]  K. Knudsen,et al.  2,3,7,8-Tetrachlorodibenzo-p-dioxin Blocks Androgen-Dependent Cell Proliferation of LNCaP Cells through Modulation of pRB Phosphorylation , 2004, Molecular Pharmacology.

[55]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[56]  J. Ni,et al.  Functional Domain and Motif Analyses of Androgen Receptor Coregulator ARA70 and Its Differential Expression in Prostate Cancer* , 2004, Journal of Biological Chemistry.

[57]  L. Seymour,et al.  Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  R. Heinrich,et al.  Control of MAPK signalling: from complexity to what really matters , 2005, Oncogene.

[59]  N. Sonenberg,et al.  Regulation of cap-dependent translation by eIF4E inhibitory proteins , 2005, Nature.

[60]  Renate Hagedorn,et al.  Representing model uncertainty in weather and climate prediction , 2005 .

[61]  S. Srivastava,et al.  Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. , 2005, Endocrine-related cancer.

[62]  F J Doyle,et al.  Model identification of signal transduction networks from data using a state regulator problem. , 2005, Systems biology.

[63]  A. Aderem.  Systems Biology: Its Practice and Challenges , 2005, Cell.

[64]  Kenneth N Ross,et al.  Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. , 2006, Cancer research.

[65]  I. H. Koumakpayi,et al.  Expression and Nuclear Localization of ErbB3 in Prostate Cancer , 2006, Clinical Cancer Research.

[66]  Bela Novak,et al.  Downregulation of PP2ACdc55 Phosphatase by Separase Initiates Mitotic Exit in Budding Yeast , 2006, Cell.

[67]  C. Haiman,et al.  Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[68]  T. Golub,et al.  Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. , 2006, Cancer research.

[69]  W. Gerald,et al.  Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer , 2006, Proceedings of the National Academy of Sciences.

[70]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[71]  J. Stelling,et al.  Ensemble modeling for analysis of cell signaling dynamics , 2007, Nature Biotechnology.

[72]  Deyan Luan,et al.  Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies , 2007, PLoS Comput. Biol..

[73]  Christopher R. Myers,et al.  Universally Sloppy Parameter Sensitivities in Systems Biology Models , 2007, PLoS Comput. Biol..

[74]  Edward C Stites,et al.  Network Analysis of Oncogenic Ras Activation in Cancer , 2007, Science.

[75]  J. Bartlett,et al.  Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer , 2007, British Journal of Cancer.

[76]  J. Varner,et al.  A Test of Highly Optimized Tolerance Reveals Fragile Cell-Cycle Mechanisms Are Molecular Targets in Clinical Cancer Trials , 2008, PloS one.

[77]  Karen E. Knudsen,et al.  AR, the cell cycle, and prostate cancer , 2008, Nuclear Receptor Signaling.

[78]  Gopal Singh,et al.  eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling , 2008, Molecular Cancer Therapeutics.

[79]  Masa Tsuchiya,et al.  Signaling Flux Redistribution at Toll-Like Receptor Pathway Junctions , 2008, PloS one.

[80]  P. Russell,et al.  Role of the Akt pathway in prostate cancer. , 2009, Current cancer drug targets.

[81]  Boon Chuan Low,et al.  Pathway sensitivity analysis for detecting pro‐proliferation activities of oncogenes and tumor suppressors of epidermal growth factor receptor‐extracellular signal‐regulated protein kinase pathway at altered protein levels , 2009, Cancer.

[82]  Masa Tsuchiya,et al.  Predicting Novel Features of Toll-Like Receptor 3 Signaling in Macrophages , 2009, PloS one.

[83]  Masa Tsuchiya,et al.  Can Complex Cellular Processes be Governed by Simple Linear Rules? , 2009, J. Bioinform. Comput. Biol..

[84]  Jeffrey Varner,et al.  Modeling and Analysis of the Molecular Basis of Pain in Sensory Neurons , 2009, PloS one.

[85]  K. Schulze-Osthoff,et al.  Switching Akt: from survival signaling to deadly response , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[86]  D. Lauffenburger,et al.  Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data , 2009, Molecular systems biology.

[87]  Dag Wedelin,et al.  Benchmarks for identification of ordinary differential equations from time series data , 2009, Bioinform..

[88]  Roland Eils,et al.  Optimal Experimental Design for Parameter Estimation of a Cell Signaling Model , 2009, PLoS Comput. Biol..